In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

India introduces Qartemi a groundbreaking CAR-T cell therapy to fight advanced blood cancers like B-cell Non-Hodgkin Lymphoma ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

Dr Matthew McKinney reflects on the mentorship and diverse experiences that shaped his philosophy toward patient care and ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

After 14 years of cancer treatment, and with few options left, CAR T-cell therapy puts a patient lymphoma into remission.

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...